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Abstract  
 
The present work focuses the optimization of the production of human Leukemia 
Inhibitory Factor (hLIF) by human embryonic kidney 293 (HEK293) - EBNA1 cell line 
cultured as suspension aggregates in spinner flask. The effects of initial cell density and 
feeding-regime in cellular growth and productivity were evaluated.  
A first phase occurs until the end of exponential growth in medium containing 
serum, being followed by puromycin selection of cells containing hLIF plasmid. A 
second phase, the production phase, is developed under serum-free conditions. Three 
initial cell densities (2×104 cells.mL-1, 2×105 cells.mL-1 and 2×106 cells.mL-1) were 
tested and the effect on maximum cell density and cell aggregate size distribution was 
evaluated. The inoculum of 2×105 cells.mL-1 led to final higher cellular densities around 
7×106 cells.mL-1 and homogeneous aggregates around 278 µm were observed. The 
effect of the feeding-regime was then studied for the production of recombinant hLIF 
with an initial cell density of 2×105 cells.mL-1 by performing metabolite analysis  
Metabolite analysis revealed the occurrence of glucose and glutamine starvation 
upon 9 and 7 days, respectively, in 25% FR. Therefore, glutamine acted as an 
alternative carbon, energy and aminoacid source in HEK293-EBNA1 growth. Observed 
lactate levels were bellow the inhibition limit concentrations (30 mM 1).  
HEK293-EBNA1 did not seem to be affected by the produced levels of ammonia.  
In conclusion, the 25% feeding regime at 2×105 cells.mL-1 initial cell density 
lead to the higher viable cell densities, either along culture time at growth and at 
production phase, with aggregates in suspension below necrotic diameters. This 
experiment conditions also allowed achieving the higher LIF volumetric productivity, 
125 ± 2.2 ng.mL-1. 
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Resumo  
 
Este trabalho tem como objectivo a optimização de condições de produção do 
Factor Inibitório da Leucemia (hLIF, do inglês “Leukemia Inhibitory Factor”) através 
da linha celular de rim embrionário humano 293 (HEK293, do inglês “human 
embryonic kidney 293”) - EBNA1 cultivada sob a forma de agregados em suspensão 
em frasco agitado. Foram estudados os efeitos da densidade inicial de inóculo celular e 
regime de alimentação no crescimento e produtividade. 
Uma primeira fase decorre até ao final do crescimento exponencial em meio 
suplementado com soro, seguindo-se de uma selecção por puromicina para as células 
portadoras do plasmídeo com hLIF. A segunda fase, de produção, decorre em meio sem 
soro. São testadas três densidades de inóculo (2×104 células.mL-1, 2×105 células.mL-1 e 
2×106 células.mL-1) de modo a avaliar a sua capacidade de expansão celular e 
distribuição dos tamanhos dos agregados celulares. O inóculo de 2×105 células.mL-1 
permitiu a obtenção de uma concentração celular final de aproximadamente  
7×106 células.mL-1 e agregados celulares homogéneos com cerca de 278 µm. O efeito 
do regime de alimentação foi estudado na produção de hLIF recombinado para a 
densidade de inóculo de 2×105 células.ml-1, através da análise de metabolitos. 
A analise de metabolitos revelou o esgotamento de glucose e glutamina após 9 e 
7 dias, respectivamente, no regime da alimntação de 25%. Assim, a glutamina actua 
como fonte de carbono, energia e aminoácidos alternativa no crescimento das células 
HEK293-EBNA1. Os níveis de lactato observados foram abaixo das concentrações 
inibitórias (30 mM 1). Aparentemente, as células HEK293-EBNA1 não foram afectadas 
pelos níveis de amónia produzidos. 
Em conclusão, o regime de alimentação de 25% no inóculo de 2×105  
células.mL-1 obteve as mais elevadas densidades celulares, tanto durante o tempo de 
cultura relativo ao crescimento como à fase de produção, com agregados em suspensão 
abaixo do tamanho de necrose. Estes condições permitiram alcançar a produtividade 
volumétrica de hLIF mais elevada, 125 ± 2,2 ng.mL-1. 
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1. Introduction 
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Over the past two decades, biopharmaceuticals like recombinant proteins (r-
proteins) have gained increasing importance for therapeutic applications. The overall 
number of proteins either approved or launched into clinical trials has continually 
increased over this period, representing an annual global market that is now valued to be 
more than 34 billion € with an annual sales increase of about 20%. Currently, about 
60% of all recombinant therapeutic proteins are produced in mammalian cell systems, 
due to the ability of mammalian hosts to generate high-quality proteins that are similar 
in their biochemical properties to the naturally occurring forms 2. This growing demand 
for high-quality recombinant therapeutics is driving the research and development of 
mammalian-cell-based technological systems for enhanced production yields. 
In 1997, sales of biotherapeutics produced by cell culture were 2.2 billion € 
whereas E. coli based biotherapeutics amounted to 1.8 billion € 3. By 2006, production 
of therapeutic proteins by mammalian systems reached 14 billion € 4. 
(original currencies in USA dollar, converted to Euro in November 2009) 
 
 
1.1. Animal cells and Recombinant Proteins 
 
One major advantage of using mammalian cells in protein production is directly 
related to the correct assembling and folding of recombinant polypeptides, as well as 
additional critical post-translational modifications, that are usually strictly required for 
biological activity 5. Most proteins are indeed glycosylated, and all these glycosylations 
from the single sugar to the many branched or linear chains, exhibiting particular O- or 
N-linkage 6, 7, have consequently made r-proteins more complex to engineer than 
initially thought. As an example, the appropriate glycosylation of recombinant 
erythropoietin (EPO), which has been approved as a drug for anaemia and cancer, has 
been shown to be critical for its activity and longevity of action 8. However, there are 
many examples where therapeutic products have failed in clinics because of their 
defective glycolysation processing 9. Many early attempts at introducing protein 
therapeutic molecules failed because the protein drug molecules were recognised as 
nonhuman and led to an immune response against the drug itself. As a result, most 
proteins used in clinical trials now are primarily human or are humanised, even if the 
original ‘proof of concept’ work was done with nonhuman proteins. The 
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immunogenicity of mouse antibodies in humans was one of the major reasons why early 
monoclonal antibodies did not deliver the anticipated therapeutic benefits 10. 
Mammalian cell cultures are particularly useful because the proteins are often 
made in a properly folded and glycosylated form, thus eliminating the need to renature 
them. Eukaryotic cells are also useful for addition of fatty acid chains and for 
phosphorylating tyrosine, threonine and serine hydroxyl groups 11. 
In contrast to lower eukaryotes or prokaryotes, mammalian cells provide active 
r-proteins that possess relevant post-translational modifications. Even if necessary 
glycosylation for stability or proper folding (e.g. EPO and human chorionic 
gonadotropin) can often be provided by recombinant yeast, mold, insect or mammalian 
cells, only mammalian secreted proteins are properly glycosylated with D-mannose 
sugars covalently bound to asparagine-linked N-acetyl-D-glucosamine molecules 12. 
Although fungal excreted enzymes often show the same type of glycosylation 13, 
sometimes additional carbohydrates linked to the oxygen of serine or threonine are 
present in fungal proteins 14. Glycosylation also affects pharmacokinetics (residence 
time in vivo) 15. Other modifications, can as well confer stability enhancement against 
proteolytic attack like terminal sialic acid addition on EPO 16, human tissue 
plasminogen activator (tPa) 17 and interferons 18 (with regard to activity, human EPO is 
1000-fold more active in vivo than its desialylated form but they both have similar in 
vitro activities 19 
Mammalian cells have have high productivities of 20-60 pg.cell-1.day-1 of 
recombinant protein. tPa was produced in Chinese Hamster Ovary (CHO) cells at  
34 mg.L-1 with an overall yield of 47%. Although production in E. coli was at a much 
higher level (460 mg.L-1), recovery was only 2.8% due to production as inclusion 
bodies and low renaturation yields 20. r-protein production in mammalian cells rose 
from 50 mg.L-1, in 1986, to 4.7 g.L-1, in 2004, mainly due to media improvements 
yielding increased growth 21. A titre of 2.5-3 g.L-1 protein in 14 day CHO fed-batch 
shake flask culture was achieved using Fe2(SeO3)3 as ionic carrier 22. A number of 
mammalian processes are producing 3-5 g.L-1 and, in some cases, protein titres have 
reached 10 g.L-1 in industry 23. A rather new system uses a human cell line known as 
PER.C6 of Crucell Holland BV, which, in cooperation with DSM Biologics, was 
reported to produce 15 g.L-1 24 and then later, 26 g.L-1  of a monoclonal antibody 25. 
Significant improvements have been made in r-protein volumetric and specific 
productivities, in great part due to the increase of cell viability and maintenance in 
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culture for long term. Cell growth in standard production culture systems can be divided 
into four phases, i.e. lag, exponential, stationary and decline or death phase. 
Long lag phases are undesirable, therefore high growth rates are essential at the 
beginning of a process to achieve enough cells in order to maximize the production of 
the desired bio-product. Uncontrolled proliferation beyond a certain desired cell density 
is also undesirable due to nutrient and oxygen depletion, toxic metabolite accumulation, 
cell death, and degradation of the product 26-28. In Figure 1.1 is represented the effect of 
engineered rCHO cells for improved culture characteristics, resulting in an enhanced 
lifespan and production. 
 
 
Figure 1.1 – Schematic depiction of the effect of engineering rCHO cells for improved culture 
characteristics. Engineering rCHO cells results in the enhancement of culture longevity, which reflects 
on the production titre. Adapted from Mohan et al 29. 
 
Proliferation control strategies are typically implemented in the mid- or late-
phases of exponential growth and have been shown to improve both the productivity 
and duration of production processes. If cell engineering is not used in conjunction with 
the right conditions, no significant improvement in protein production is achieved. 
Strategies to extend culture longevity could be tried, such as overexpression of anti-
apoptotic genes, down-regulation of apoptotic effector molecules, overexpression of 
pyruvate carboxylase, down-regulation of lactate dehydrogenase-A (LDH-A), and 
down-regulation of cold-inducible RNA-binding protein (CIRP ) 29. 
 
Medium composition, especially serum components, affects the concentration of 
autocrine signalling factors determinant of growth 30, 31 that could seriously have an 
important role in culture kinetics. 
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Several factors were identified to affect the proliferative capacities in different 
tissues, namely the vascular endothelial growth factor (VEGF), the hepatocyte growth 
factor (HGF), and the basic fibroblast growth factor (bFGF) 32-35. More recently, 
Herbert et al 36 reported that human adipose-derived stromal/stem cells (hASCs) in 
vitro cells supplemented with EGF and bFGF significantly increased proliferation by up 
to three-fold over 7-8 days. 
 
 
1.2. Medium formulation  
 
Although serum is a common component of culture medium containing a set of 
important nutrients and other elements as anti-apoptotic factors that protect cells from 
apoptosis 37, strict regulatory requirements restrict the use of serum- or protein-free 
media for the large-scale culture of cells. Hence strategies have been developed to fulfil 
these requirements. The apoptosis modulation is a variable intensively studied and 
several strategies have been proposed, like the manipulation of external cellular 
environment through media supplementation or by manipulation of intracellular 
environment using genetic engineering 29. Serum-free suspension processes are often 
the preferred mode for the production of animal recombinant proteins due to its easy in 
scale-up process and operation, simplicity in downstream processing and reduced risk 
of virus contamination. 
  
A major allocation of resources in culture lifespan enhancements has been used 
for anti-apoptosis cell engineering to tackle the problem of programmed cell death 
occurring under stressful conditions. Several studies have already demonstrated the 
successful adaptation of Human Embryonic Kidney cells (HEK293) cells growth in 
serum-free, keeping the protein quality 1, 38. Even though serum is a cell protector that 
increases cell viability and proliferation 27, 37, new formulations must be developed to 
provide less complex feedstream for downstream processing and allow improvements in 
r-protein yields. 
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1.3. Cell metabolism 
 
Glucose and glutamine are the main nutrients of animal cells and both can 
interchangeably be used as energy sources. Glucose is either utilized trough the pentose 
phosphate pathway to supply nucleotides for biosynthesis 39, 40 or through the glycolysis 
pathway to provide metabolic intermediates, such as pyruvate, and energy. Pyruvate is 
preferably converted to lactate and fatty acids, but it can also become oxidized in the 
tricarboxylic acid (TCA) cycle 41, 42 originating H2O and CO2, followed by the 
formation of high-energy phosphate bonds by phosphorylation of ADP to ATP (coupled 
to the transfer of electrons from reduced coenzymes to molecular oxygen) via the 
electron transport chain. On the other hand, glutamine is oxidized to CO2 and is a key 
aminoacid, since it is consumed at a higher rate than other amino acids 43. Glutamine 
can be used to produce other amino acids or to be incorporated into the biomass; 
however the majority is converted to glutamate. Then glutamate can be converted to  
α-ketoglutarate and enter the TCA via one of the two next pathways: production of 
alanine or by a more efficient process that results in the production of an additional 
molecule of ammonia 44.Also the overall amino acids in media composition is important 
in product formation 
Within these catabolic pathways, comparable for different animal cell types 45-48, 
lactate and ammonia are presented as major metabolic waste products, to an extent that 
is specific for each cell line 49, due to the different sensitivities of key enzymes in the 
glucose and glutamine metabolic pathways and respective shifts in response to the 
environment signals. Glucose and glutamine metabolism is resumed in Figure 1.2 (more 
details for each molecule catabolism are presented in Appendix, 6.1). 
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Figure 1.2 – Schematic diagram of simplified reaction network for animal cell metabolism. F1 to 
F26 are respective to mediating enzymes involved in the metabolism. Adapted from Xie and Wang 50 
 
 Considering metabolic engineering as a tool to overcome these limitations 29, 
indirect increases in cell growth and volumetric production had been achieved, mainly 
by inhibiting the accumulation of these toxic metabolic by-products, lactate and 
ammonium, which showed significant results. The strategies are generally based on: 
 - reducing the accumulation of lactate in cell culture media; lactate accumulation 
acidifies the medium and hence requires the addition of  more  base (increasing 
the  osmolality  and  adversely  affecting  the  cell growth and product quality); 
 - improving the efficiency of the primary metabolism, by redirecting cells into 
pathways using energy more efficiently. 
 
 Some examples can be the LDH-A knock out (reducing glucose consumption 
rate, thus reducing lactate production) within normal proliferation kinetics 51, the 
overexpression of urea cycle enzymes like carbamoyl phosphate synthase and ornithine 
transcarbamoylase (reducing accumulation of ammonia ions) 52, or the overexpression 
of pyruvate carboxylase to increase glucose flux into the tricarboxyilic acid cycle 53. 
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These examples demonstrate the potential to overcome, in large-scale production of 
recombinant heterologous proteins, toxic metabolic by-product accumulation, inhibitors 
of cell growth. 
 
 
1.4. Systems for Recombinant Protein Expression 
 
Traditionally, in order to obtain sufficient amounts of protein for structure and 
biological activity analysis in high-throughput screenings, one needs to go to through 
the long, costly and time-consumption process of stable transfectoma isolation and 
characterization 54, 55. 
Gene expression by large-scale transfection of mammalian cells is becoming an 
established technology for the fast production of r-proteins. However, efforts are still 
needed to optimize production parameters in order to maximize productivities while 
maintaining product quality 56. 
 
Until 2001, transient gene expression (TGE) have been exploited only for the 
synthesis of smaller quantities of r-proteins using different cell lines, e.g., COS1 cells 57, 
HEK293 58, and Baby Hamster Kidney (BHK) cells 59. However, this technique has 
recently begun spreading to a large-scale as a powerful technology to generate large 
amounts of r-proteins within a few days 54, 55, 59-64. 
Moderate quantities (1-500 mg) of complex r-proteins for functional and 
structural analysis 65, 66 can now be easily obtained through TGE in animal cells, mostly 
because of its cost-effectiveness and speed compared to the time-consuming and  
laborious  establishment  of  stable  cell  clones  59. Furthermore, when a large number 
of different proteins or variants of the same protein need to be tested, the transient 
system can be efficiently applied in a high-throughput approach for parallel evaluation 
54, 67
. 
 
                                                 
1
 COS is an acronym, derived from the cells being CV-1 (simian) in Origin, and carrying the SV40 
genetic material 
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For an optimal large-scale transient transfection and r-protein expression on 
mammalian cells, four key aspects need to be taken into account, namely: 
- the cell line; 
- the expression vector; 
- the transfection vehicle; 
- the culture medium. 
 
The human embryonic kidney 293, HEK293 68 cell line, and the subclone 293 
expressing the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) cell lines, became 
important for production of viral vectors for gene therapy and also for expression of r-
proteins, e.g. using extra chromosomal EBV based vectors 69. The HEK293(EBNA1) 
expression system exhibits many advantages compared to CHO or BHK systems. For 
example, it is of human origin, it exhibits high transfection efficiency, have autonomous 
replicating vectors available, it is useful for expressing human proteins and, finally, the 
cells are relatively easy to grow in serum-free suspension culture 70, 71. Moreover, two 
genetic variants, the 293E and the 293T cell lines, expressing the EBNA1 or the SV40 
large-T antigen, respectively, allow episomal amplification of plasmids containing the 
viral EBV (293E) or SV40 (293T) origins of replication. Thus, they are expected to 
increase r-protein expression levels by permitting more plasmid copies to persist in the 
transfected cells throughout the production phase 72.The second important issue for high 
level r-protein expression is to use vectors with promoters that are highly active in the 
host cell line, such as the human cytomegalovirus (CMV) promoter 73. This promoter is 
particularly powerful in HEK293 cells where it has been shown to be strongly 
transactivated by the constitutively expressed adenovirus E1a protein 74. A highly 
efficient expression cassette using this promoter was recently described that provides 
adenovirus-mediated transgene expression levels reaching up to 20% of total cell 
proteins 75, 76. HEK293-EBNA1 cells and oriP plasmid constitute a powerful transient 
expression system in which the episomal replication of plasmid is  initiated  by EBNA1  
binding  to  oriP  77. HEK293-EBNA1 expression system is schematically represented 
in Figure 1.3. Transfection productivity should be considered together with the cell 
construct when evaluating productivities. 
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Figure 1.3 – Schematic representation of the HEK293-EBNA1 transient expression system. The 
plasmid is inserted into cell, migrating to nucleus, where the target sequence is transcript and 
subsequently expressed as peptide by cytoplasm machinery, processed and secreted. 
 
Durocher el al formulated an oriP plasmid pTT, derived from a commercially 
available pCEP4, which was able to enhance expression of protein by several folds 54. 
The third aspect is related to gene transfer reagent efficacy. Even though many highly 
effective gene transfer reagents are commercially available, only a few are cost effective 
when considering operations at the multi-litre scale. 
 
There are several advantages of episomal vectors: first, the inserted gene of 
interest cannot be interrupted or subjected to regulatory constraints, which often occur 
from integration into cellular DNA. Secondly, the presence of the inserted heterologous 
gene does not lead to rearrangement or interruption of the cell's own important regions. 
Thirdly, episomal vectors persist in multiple copies in the nucleus, resulting in 
amplification of the gene of interest, whenever the necessary viral trans-acting factors 
are supplied 72. Finally, in stable transfection procedures, the use of episomal vectors 
often results in higher transfection efficiency than the use of chromosome-integrating 
plasmids 78, 79. Furthermore, episomal vectors are plasmid constructions that replicate in 
both eukaryotic and prokaryotic cells and can therefore easily be “shuttled” from one 
cell system to another. This feature and the fact that some episomal vectors can transfer 
large amounts of DNA allow applications, such as screening of cDNA libraries 80-82. 
Episomal vectors recur to cellular enzymes for replication and repair, being powerful 
tools for studying DNA replication or mutagenesis 83, 84. 
 
 The stability of the episomal vectors might be questioned
be critical. As reviewed by 
viral elements necessary and sufficient for stable episomal maintenance of viral DNA in 
the cell. This stable episomal maintenance reflects the sum of plasmid replication and 
efficient segregation to the daughter cells. The better
would be an advantage, once that HEK293, as well as CHO, are the preferred cells to 
TGE owing to their high transfectability and the ability of these cells to support high
density in growth in suspension 
 
 
1.5. Culture syst
 
Depending on the nature of cells in culture, if they are anchorage
they grow in suspension, 
industrial scale, as shown in 
cell adhesion and retention in suspension cultures, like microcarriers, being possible to 
scale-up 86, 87, but with the disadv
aggregates.  
Figure 1.4 – Cell cultivation methods applicable for expansion and differentiation of stem cells
Adapted from Ulloa-Montoya et al.
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The HEK293 cell line was adapted to growth in suspension 70, forming cell 
aggregates as a self-immobilization strategy, as presented in Figure 1.5. This can be 
considered as an alternative approach to producing bioactive cellular products 89-91. 
Whereas in perfusion culture systems more complex strategies must be adopted to 
perform cell retention (as spin filters and others) 92, in fed-batch systems, cell 
sedimentation can be easily used regarding medium change. HEK293 cells were already 
setup until 100 litre  scale transient transfection in a standard stirred bioreactor, 
demonstrating not only the scale-up availability of cellular aggregates suspension, but 
also the robustness of large scale transient gene expression 64.  
 
 
Figure 1.5 – Scanning electron microscopic observations of the HEK 293 cell aggregates in 
perfusion culture. a) 5 days after inoculation, b) 17 days after inoculation. The scale bars in a) and b) 
indicate 62 and 99 µm, respectively. Adapted from Liu et al. 93. 
 
Suspended mammalian cell cultures are normally cultivated in glass or stainless-
steel stirred tank bioreactors, properly designed with impellers that minimize shear 
forces 94. These bioreactors can be operated in three different modes, including batch, 
fed-batch, or perfusion, where each one has its advantages and disadvantages 95. 
Homogenous perfusion mode is usually known by achieving higher cell density and 
productivity than either the batch or fed-batch designs, in relatively small volumes. In 
perfusion mode, high cell number and productivity, as well as steady supply of nutrients 
and continuous removal of metabolic by-products must follow the growth kinetics and 
production phase. Perfusion is also characterized by a medium dilution rate exceeding 
that of cellular growth, needing a dependable separation approach to retain cells in the 
bioreactor. In batch or fed-batch, the metabolite removal is not fully supported, being a 
limitation overcame in a perfusion design. 
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In laboratory scale, spinner flasks, simple stirred vessels, operating as fed-batch 
cultures are a simple and economic way to study basic parameters before undergo scale-
up strategies at higher volumes. Their relatively homogenous nature makes them 
uniquely suited for investigations of different culture parameters (e.g. dissolved O2, pH, 
temperature, agitation rate, serum components medium exchange rates, etc) that may 
influence the viability and turnover of cells in culture 42, 96. Another important parameter 
to control is the particle size and their density in suspension, because it must be 
considered for large-scale cell retention 92 during feeding and other operations.  
Agitation rate is also an important variable to consider in suspension stirred 
culture. Despite the high agitation rate promotes frequent collisions between cells or 
cells and microcarriers favouring proliferation and avoiding sedimentation, this could be 
a critical factor to consider in terms of hydrodynamic shear stress, because higher 
stirring velocities may affect cell membrane integrity, as well as cell function 97. In 
order to better control the culture environment, to minimize shear stress and bursting 
bubbles, some authors have studied the possibility of add protective agents such as 
surfactants (and also serum, which besides its nutritional role, has some cell protective 
effects, despite the technical disadvantages of its use, as previously mentioned) 98. 
 
 
1.6. Leukemia Inhibitory Factor 
 
The Leukemia Inhibitory Factor (LIF) is a variably glycosylated, 38-67 kDa 
polypeptide originally identified as a proliferation inhibitor and differentiation inducer 
of the mouse M1 myeloid leukemia cell line 99-101. The mature LIF molecule measures 
179 amino acid (aa) residues in length with multiple potential N-linked and O-linked 
glycosylation sites plus six conserved cysteines that form three intramolecular disulfide 
bridges. Mature mouse LIF is 78% identical to human LIF at the aa sequence level 102, 
103
. The tertiary structure of human LIF (hLIF) is presented in Figure 1.6. 
 Figure 1.6 – 3D structure of human Leukemina Inhibito
LIF appears to be a generalized stem cell factor as many of its actions are 
mediated via stem cells or proge
tissues 104, 105. For example, LIF
stem cells in spleen and bone marrow 
monocytic series, embryonic stem cells, embryonic carcinoma cells, on a majority of 
lymphocytes, myoblasts, hepatocytes, osteoblasts, adipocytes and adrenal cortical cells 
107
. Partially, the transduction mechanism
6 (IL-6) 108 which also uses
immediate early response 
The mechanism of action of LIF is presented schematically in 
association of LIF with its heterodimeric receptor, which consis
receptor subunit β (LIFRβ) and IL
several intracellular signalling pathways, including the signal transducer and activator 
of transcription 3 (STAT3) pathway, the Ras/ERK pathway and the PI3 kinase pathway 
111
. However, the differentiation 
shared by IL-6 class cytokines
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 gpl30 for signal transduction 109 and triggers the same 
during induced differentiation of murine leukemic cells 
ts on a LIF
-6 signal transducer gp130, results in the activation of 
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.  
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Figure 1.7. An 
-specific 
 Figure 1.7 – Intracellular signaling pathways activated by LIF. 
 
The cytokine LIF and its downstream effector STAT3 are essential for
maintenance of pluripotency 
transcription factor Oct3/4 for 
documented. However, LIF is not involved  in  self
suggesting  that  other  pathways
importance of other signal 
protein) and Wnt signalings, as well as novel transcription 
now being recognized 111
involved in the intracellular signalling 
pluripotent mouse and human ES cells
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Adapted from Okita et al
in mouse embryonic stem cells. The requirement
embryonic stem cells (ES) cell pluripotency is also well 
-renewal  of  human  ES  cells,  
 must play an important role in this process. 
transduction pathways, including BMP (bone morphogenetic 
factors such 
. Figure 1.8 briefly overviews the complexity of signals 
pathways that contribute to self
. 
 
111
. 
 
 for the 
The 
as Nanog, is 
-renewal of 
 Figure 1.8 – Potential crosstalk between intracellular signalling pathways in mouse
Adapted from Okita et al 111. 
 
About LIF action in the organism development, it is known that:
- it can inhibit the growth and induce macrophagic differentiation in murine 
leukemic M1 cells 112, while preventing the differentiation in normal totipotential 
embryonic stem cells 113; 
- it inhibits the induced different
carcinoma cells 115 selectively inhibiting the formation of primitive ectoderm, while 
permit the differentiation of primitive endoderm 
- during embryonic development, LIF is expressed in bl
cylinder 106 and might play a crucial role in implantation process 
 
Overall, the establishment of an effective and reproducible platform for the 
production of hLIF will allow to produce large amounts of 
house, avoiding the need to acquire large amounts of th
cytokines/growth factors) to commercial sources.
adapted for the production of other cytokines/growth factors to be used in stem cell 
culture, but also molecules 
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2.1. Cell line 
 
HEK293-EBNA1 cells were a kind gift from W. Mueller and M. Hafner, GBF, 
Braunschweig – Germany. These cells were previously transfected and contain copies 
of a pCMV plasmid encoding for human Leukemia Inhibitory Factor (hLIF) and 
containing a resistance marker for purymicin. HEK293-EBNA1 cells were kept frozen 
at – 80 ºC until further use. 
 
 
2.2.  HEK293 expansion in static conditions 
 
HEK293 were passed routinely and expanded as adherent monolayer cultures in 
T-flasks (75 cm2) at 37 °C in a humidified 5% CO2 atmosphere. Cells were cultivated in 
Dulbecco's modified Eagle's medium (DMEM, glucose at 22 mM) supplemented with 
10% (v/v) fetal bovine serum (FBS) (Gibco®), 1% (v/v) penicillin  
(50 U/mL)/streptomycin (50 U/mL) (Gibco®) and 1% glutamine 200 mM (Gibco®). 
Trypsinization was performed using a 0.25% (w/v) trypsin-phosphate buffered saline 
(trypsin/PBS) solution, and the cells were passaged every 4–5 days (confluence of  
80-90%) at a seeding density of 2×105 cells.mL-1 in T-flasks of 75 cm2. In each passage, 
cell viability was determined in a hemocytometer using the trypan blue dye exclusion 
test under an optical microscope (Olympus CK40). 
 
 
2.3. HEK293 expansion under dynamic conditions 
 
2.3.1. Spinner flask culture system 
HEK293 expansion was performed in 100 mL spinner flasks where the cells 
were able to grow in suspension as aggregates (Figure 2.1). The spinner flask is 
equipped with an impeller with 90º normal paddles (Flat Bottom Adjustable Hanging 
Bar Spinner Flask Complete – 100mL, from Bellco®) and a magnetic stir bar. The 
 glass surface of the spinner flask was 
the adhesion of cells and aggregates to the glass walls. Before 
culture, spinner flasks were washed with Milli
 
Figure 2.1 – Spinner flasks used for 
 
Cells were  grown  at  37° 
replenished  daily  with  fresh  medium beginning  on  the  third  
Agitation rate was set at 80 rpm
 
2.3.2. Feeding
Spinner flask medium was replaced 
changed on a daily routine starting on the second day of culture growth. Three feeding 
regimen were tested: 25%, 50% and 75%, either in the initial cell density of 
2×105 cells.mL-1 and 2×106
step of sedimentation of 30
fraction according with the feeding regime in order to keep a constant 
100 mL. 
 
2.3.3. Samplin
Duplicate samples of 1 ml of e
Samples were centrifuged at 1500 rpm for 
5 minutes at 37º C with half of initial volume of a 0.25% trypsin solution (1% when 
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occurring larger aggregates than 150 µm), followed by addition of ½ of initial volume 
of medium (with FBS) to stop enzymatic activity. Cells were then ressuspended for 
counting viable and dead cells in suspension using the trypan blue exclusion method. 
The supernatants were kept at -20º C for metabolite analysis. 
Cell viability across experiments and trypan blue exclusion method robustness 
was tested, as presented in Appendix, 6.2. 
 
2.3.4. Aggregate-size distribution assay 
The average diameter of the HEK293 cell aggregates in the spinner flasks was 
determined by optical analysis of 10 to 20 aggregates (essentially spherical in shape) 
recurring to a graduated ocular lens (Olympus NCWHK10X) on a optical microscope 
(Olympus CK40). Images were obtained directly from an eyepiece reticule and one 
inverted light microscope (Leica DMI 3000B) using Nikon Act-1 analysis software. 
 
2.3.5. Data analysis 
The growth kinetics of HEK293 cells cultured under stirred conditions on 
microcarriers was also characterized. Specific growth rates were calculated according to 
Equation 2.1, from Melero-Martin et al. 118: 
μ =
1
X
dX
dt
≈
2
X	 + X
X	 − X
t	 − t
   (2.1) 
 
where µ (day−1) corresponds to the value of specific growth rate at any given time point, 
t (days) the culture time and X (cells) the value of viable cell number for a specific t. 
From this, the doubling time (td) was calculated using the following Equation 2.2,  
 = ln(2) /   (2.2) 
 
For a more rigorous calculation of , a curve fitting was calculated using 
Origin software (under a test licence) within a 100 points non linear regression, using 
Logistic function, in order to reduce operator and sampling variability. This simulation 
data was plotted in Microsoft Excel and a linear regression was obtained for the 
exponential phase of growth, where the  is obtained by the slope (m) in the linear 
regression equation:  = .  +  (see Appendix, 6.3). 
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2.3.6. Lactate Dehydrogenase activity 
Lactate dehydrogenase (LDH) is an enzyme present in the cells that catalyses the 
interconversion of pyruvate and lactate. The activity of this enzyme is a quantitative 
measurement of loss of cell viability as dead or dying cells release this enzyme. For 
determination of LDH activity levels during time in culture, a LDH analysis kit from 
Promega was used (CytoTox96 non-radioactive cytotoxicity assay). A calibration curve 
using several dilutions of cells, which were submitted to lysis, was performed according 
to manufacturer’s instructions. This test was used to confirm the accuracy of trypan blue 
assay in measuring dead cell number (see Appendix, 6.2). 
 
 
2.4. Determination of metabolite profiles during time in 
culture 
 
Glucose, lactate, glutamine and ammonia concentrations were determined in the 
supernatant samples collected throughout the experiments by using an automatic 
analyzer (YSI 7100MBS, Yellow Springs Instruments). The specific metabolic rates 
(qMet., mol.106 cells.h-1) were calculated for every time interval using the following 
equation: qMet.= ∆Met./(∆t.Xv), where ∆Met. is the variation in metabolite concentration 
during the time period ∆t and ∆Xv the average viable cell number during the same time 
period. The apparent lactate from glucose (Y’lac/glu) yield was also calculated as the ratio 
between qlac and qglu 
 
 
2.5. Recombinant hLIF expression analysis 
 
2.5.1. Cell selection at production phase in static culture 
For hLIF expression, after becoming confluent, cells were split into another flash 
where puromycin (Invitrogen®) at 0.5 mg.mL-1 was added. Then, after 3 days (with 
 cells confluent), cells were spliced and cultured with medium without puromycin. After 
3 more days, the medium wa
was collected after 2 days and filtered through a 0.
– 20 ºC. The protocol can be schematically described by 
 
Figure 2.2 – HEK293-EBNA1 growth evolution
serum-free conditions 
 
2.5.2. Cell se
culture 
HEK293 cells containing 
resistance at steady phase. Puromycin was added to culture 
24 hours later by two new media replenishments of 50% of volume, 
sedimentation step. 
The production phase occurred in ser
selection by puromycin. The culture medium 
after with 75% volume of serum
2–3 days and filtered through a 0.
protein analysis. 
 
2.5.3. Protein 
 
2.5.3.1. SDS
Protein samples 
polyacrylamide gel electrophoresis
separating gel: T = 12%, C =
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buffer. Before loading onto the gel, protein samples were mixed with protein loading 
dye containing SDS and β-mercaptoethanol and denatured at 100ºC for 5 minutes.  
Samples to be analyzed with immunoblot analysis were submitted the same 
procedure. Gel dimensions were always 73 mm × 84 mm × 100 mm. The proteins were 
separated electrophoretically within contant 80 V for 90-120 min. Protein bands were 
stained with Coomassie brilliant (Pierce®) for SDS-PAGE or transfered to 
nitrocellulose membrane for immunoblot analysis. 
 
2.5.3.2. Western Blot 
Separated proteins were transferred from an SDS-PAGE gel to BIORAD® 
nitrocellulose membrane (0.45 µm) in transfer buffer, at a constant intensity of 30V 
overnight.  
After blotting the membrane was blocked with 1x PBS buffer containing 5% 
(w/v) Bovine Serum Albumin (BSA) (milk powder). As primary antibody hLIF  
200 µg/ml (rabbit polyclonal Santa Cruz) was used in a dilution of 1:500 in 1x PBS. 
Binding of the primary antibody was detected by addition of goat anti-rabbit secondary  
polyclonal antibody (Santa Cruz), used in a dilution of 1:1000, coupled to horseradish 
peroxidase (HRP) enzyme. The target protein was finally revealed by addition of the 
substrate (Western Blotting Luminol Reagent, Santa Cruz). 
 
2.5.3.3. ELISA assay 
A Quantikine ELISA kit (R&D systems) was used for screening samples for 
human Leukemia Inhibitory Factor. The protocol and calibration curve was performed 
as recommended by the kit protocol. 
 
 
2.6. Data Analysis 
 
For cell growth and aggregate size distribution, results are presented as  
mean  ±  standard error of the mean (SEM) of two internal duplicates. For comparing 
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hLIF secretion in supernatants, internal duplicates were tested in ELISA assay, 
following further kit’s indications.  
Origin  8 software and Excel 2007 were used in order to reach a more accurate 
 value for growth experiments. The process strategy is described in Appendix, 6.3. 
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3. Results and Discussion 
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The optimum temperature and pH value for HEK293 cell culture were 
previously defined as 37° C and 7.4, respectively 93, in static culture. The agitation rate 
of 80 rpm for HEK293 cell growth in a 100 mL working volume spinner flask was 
previously optimized at BERG/IBB-IST. 
When in culture, either in static or spinner flask, the cells presented themselves 
individualized in suspension, as shown in Figure 3.1. 
 
 
Figure 3.1 – HEK293-EBNA1 cells in suspension at day 0 of culture in a spinner flask. 
 
After seeding, HEK293 cells start as a suspension culture and tend to aggregate 
if in suspension stirred culture, or to adhere to a surface under static conditions, as a 
consequence of the need of anchorage for growing. Figure 3.2 shows adherent  
HEK293-EBNA1 cells on the surface of a T-Flask. 
 
 
Figure 3.2 – HEK293-EBNA1 cells adherent to a T-flask surface at day 3 of culture. 
 
Optimization of the initial cell density and feeding regime was performed under 
dynamic conditions in a spinner flask. The results of cell expansion and recombinant 
hLIF production were then compared with the former method described for T-flask 
culture. 
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Table 3.1 – Maximal growth rates, duplication time and maximal fold increase in total cell number 
for HEK293-EBNA1 cell growth with a feeding regimen of 25% (v/v) daily. 
Initial Cell Density µ max (h-1) td (h) 
Fold 
Increase 
X max 
(106 cells.mL-1) 
X prod 
(106 cells.mL-1)
 
2×106 cells.mL-1 0.021 33.0 2.17 7.73 4.35 
2×105 cells.mL-1 0.055 12.7 49.6 9.32 6.54 
2×104 cells.mL-1 0.0010 510 29.0 0.188 0.160 
 
Having similar specific growth rates, initial cell densities of 2×105 cells.mL-1 
and 2×106 cells.mL-1 need different times to achieve the plateau, limiting the F.I. of 
respective cultures. Lee et al. 120 reported and discussed that the specific growth rate of 
hybridoma cells in a batch suspension culture was found to increase with increasing 
initial cell density up to a certain cell density level (about 5.4×105 cells.mL-1) and then 
to decrease with further increases in initial cell density, as it was observed within the 
HEK293-EBNA1 fed-batch suspension culture experiments. Three reasons have been 
proposed to explain why the specific growth rate increases with increased initial cell 
density up to a certain level. First, cells can secrete autocrine growth factors (i.e. 
mitogens) that stimulate cell growth during the initial lag phase. Second, cells possess 
detoxification ability in their environment. Third, there is a specific cell-cell interaction. 
Nevertheless, further increases in initial cell density result in a reduced specific growth 
rate.  Lee et al. 120 also suggests that high maintenance energy and the accumulation of 
toxic metabolites  at  high  initial  cell  density  reduce  specific growth  rate. 
 
Moreover, the daily medium change modifies the concentration of autocrine 
signal factors in the medium 30, 31 and this could affect HEK293-EBNA1 cell expansion. 
Chioni et al 121 reported that FGF-10 acts as a paracrine signalling molecule and seems 
to play an important role in animal cell proliferation. The concentration of this or 
equivalent protein in the bulk can be growth inhibitory for the inoculum of  
2×106 cells.ml-1 and not sufficient for cell proliferation for the inoculum of 2×104 
cells.mL-1. 
 HEK293-EBNA1 cells
cultivated in suspension in 
distribution dynamics is described bellow in 
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Figure 3.4 – Effect of initial cell density on aggreg
suspension stirred culture. Inoculums of 
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 showed a strong tendency to form aggregates when 
serum-containing medium 93. The HEK293 aggregate size
Figure 3.4 and Figure 3.5. 
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cell density once the portion of cells involved in aggregate formation was in great 
majority. 
The standard deviation traduces the heterogeneity of the cellular aggregates, 
only having some homogeneity in the experiment with higher inoculum  
(2×106 cells.mL-1). The microscopy images of the HEK293-EBNA1 aggregates are 
shown in Figure 3.5. 
 
Day 5 Day 12 Day 17 
 
A 
B 
 C 
Figure 3.5 – Optical microscopy observations of HEK293-EBNA1 cell aggregates at day 5, 12 and 
17 of suspension stirred culture. A – inoculum of 2×104 cells.mL-1; B – inoculum of 2×105 cells.mL-1; C 
– inoculum of 2×106 cells.mL-1 with an agitation rate of 80 rpm and a feeding regimen of 25% of daily 
medium change. The images at day 17 are in serum-free conditions. Scale bar represents 100 µm length. 
 
At day 5, the number of aggregates directly increases with initial cell density 
(comparing Figure 3.5A with Figure 3.5C or Figure 3.5B). At day 12, the differences in 
morphology of aggregates became clear, being smaller with the increase of the initial 
cell density, and with more cells found as single cells in suspension. At 2×104 cells.mL-1 
inoculum, aggregates kept mostly unchanged from day 12 to day 17 (Figure 3.5A), but 
slightly larger aggregates occur from day 12 to day 17 (Figure 3.5B) at  
2×105 cells.mL-1. These images support the data from Figure 3.4. 
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The inoculum of 2×105 cells.mL-1 was set as the initial cell density to study the 
effect of the feeding regimen in HEK293-EBNA1 cell growth and afterwards hLIF 
production, due to its high cell expansion capacity and more homogeneous aggregate 
shape and size (presumably not leading to necrosis). 
  
 3.2. Effect of Fee
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duplication time, cell densities and FI in total cell number are compared for the FR of 
25%, 50%, 75%. 
 
Table 3.2 – Maximal growth rates, duplication time and maximal fold increase in total cell number 
for a inoculum of 2×105 cells.mL-1 at different feeding regimen in a spinner flask at 80 rpm. 
Feeding Regime µ max (h-1) td (h) 
Fold 
Increase 
X max 
(106 cells.mL-1) 
X prod 
(106 cells.mL-1)
 
25 % 0.055 12.7 49.6 9.32 6.54 
50 % 0.033 21.2 31.6 6.60 5.49 
75 % 0.021 33.7 36.8 3.96 1.53 
 
The removal and replacement by fresh medium seems to have a negative impact 
on cell proliferation diminishing the maximum fold increase attained and µ max as the FR 
increases. The dilution effect caused by fresh medium replacements over proliferative 
and anti-apoptotic autocrine factors could explain the decrease of the signalling 
pathways effectiveness activated for cell growth. Thus, this would explain the higher 
HEK293-EBNA1 cell densities observed for the feeding regime of 25%, with higher 
maintenance of autocrine factors and lower perturbation on medium composition. 
Further analysis of metabolites will show how toxic by-products, e.g., lactate and 
ammonia, may affect culture growth (see Metabolite Analysis, 3.2.1). 
 
The dynamics of HEK293-EBNA1 aggregates during the time of culture was 
studied (Figure 3.7).  
  
 (A) 
                                                      (C) 
Figure 3.7 – Effect of feeding-regime on HEK293
stirred culture in spinner flask
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(B) 
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 at 80 rpm The feeding regime of (A) 25% ( ); (B) 
ity of 2×105 cells.mL
d with the time of culture, 
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Day 5 Day 12 Day 17 
 
A 
B 
C 
Figure 3.8 – Optical microscopy observations of HEK293-EBNA1 cell aggregates at day 5, 12 and 
17 of suspension stirred culture. A – feeding regimen of 25% of daily medium change; B – feeding 
regimen of 50% of daily medium change; C – feeding regimen of 75% of daily medium change, with an 
agitation rate of 80 rpm and a start inoculum of 2 × 105 cells.mL-1 and with daily medium change. The 
images at day 17 are in serum-free conditions. Scale bar represents 100 µm 
 
As presented in Figure 3.7, Figure 3.8 shows smaller and homogeneous 
aggregates observed in the feeding regime of 25% and 50% compared to the 
heterogeneous aggregates detected with the 75% FR. The data presented seems to 
predict that considerable volume changes in the suspension culture system of  
HEK293-EBNA1 cells may have a negative effect in cellular growth leading to 
aggregate heterogeneity. Thus, the medium renewal, apparently favourable in terms of 
nutrient replenishment, can provide additional variables that can affect autocrine factors 
concentration. 
Some authors described that aggregates with diameters up to 400 µm have been 
obtained for BHK and HEK293 cells without having the formation of necrotic centres 
123, 124
. Liu et al 93 demonstrated that size variation, diffusion limitations, and cell death 
may exist at the cores of large suspended aggregates. The authors also recommended 
that the average diameter of aggregates in suspension culture should be controlled to a 
range smaller than 350 µm, as it was observed in the present work for HEK293-EBNA1 
within a feeding regime of 25% and 50% (Figure 3.7A and Figure 3.7B).  
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3.2.1. Metabolite Analysis 
Analysis of the nutrients (glucose and glutamine) consumption and production 
of catabolites (lactate and ammonia) provides additional information about nutrient 
limitations once the final cell density could not make it evident. It is important to define 
the metabolism of the HEK293-EBNA1 cells growing as suspended aggregates in 
spinner flasks in order to better understand the effect of the feeding regimen on the 
culture system. Therefore, specific glucose and glutamine consumption rates (qglu and 
qgln, respectively) as well as specific lactate and ammonia production rates (qlac and 
qamm, respectively) were determined. 
 
3.2.2. Glucose / Lactate metabolism 
Glucose and lactate concentration profiles are presented in Figure 3.9, in order to 
evaluate the primary metabolism of cells in culture for the different FR at  
2×105 cells.mL-1 initial cell density. 
 
25 % FR 50 % FR 75 % FR 
Figure 3.9 – Glucose consumption and Lactate production profiles in suspension stirred 
culture of HEK293-EBNA1 cell aggregates in spinner flask. The initial cell density was  
2×105 cells.mL-1. The blue line corresponds to the growth phase in medium supplemented with FBS and 
the red line corresponds to the production phase under serum-free conditions. 
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As expected, the feeding regimen affects the availability of glucose in the 
medium: the higher is the volume of fresh medium renewal, the higher is the glucose 
concentration available in the medium along time. In the feeding regimen of 25% 
(Figure 3.9) a significant decrease in glucose concentration was observed after day 3 of 
cellular growth, probably as a consequence of the higher viable cell density (Figure 3.6), 
and at day 9 the glucose availability in medium reached zero, keeping this level almost 
until the end of growth phase. A slightly lower decrease was found for the 50% FR, also 
with glucose levels near to zero values after day 9. In opposite, the FR of 75% could 
maintain glucose levels above 5 mM until the last day of culture. 
 
Overall, lactate concentration did not seem to have an inhibitory effect on 
HEK293-EBNA1 growth. Although Nadeau et al 125 referred the 20 mM in lactate as 
the minimum concentration to have an pronounced effect in cell viability (but not 
relevant in loss of productivity), Siegwart et al 1 registered no limitations on  
HEK293 growth with lactate concentration until 30 mM. Newland et al 126 reported that 
for tumour cells, the growth was not limited by energy production but rather by 
biosynthesis rate. Xie at al 50  showed that the ATP production per cell was 3-4 times 
higher than the theoretical ATP needed for biomass and product synthesis and active 
transport of glucose and amino acids. This over influx of glucose in the cell due to high 
glucose transport rate, either because the flux of pyruvate in the TCA cycle is limited by 
a saturated oxidative capacity or because glucose flux directed to the TCA cycle already 
produces sufficient ATP 127, but this insight cannot be linearly applied to this case, once 
it will be possible to see that even with glutamine, cell’s carbon and energy sources 
would not be enough as cell’s needs, being all available source of energy and carbon 
applied in growth and protein biosynthesis. 
As expectedly, lactate levels, higher in FR of 25% than in 50% and 75% FR are 
diminished with higher volumes of medium renewals (Figure 3.9). Even tough, all FR 
could support lactate removal, avoiding concentrations of this by-product above the 
described inhibitory levels. 
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3.2.3. Glutamine / ammonia metabolism 
Glutamine profiles reveal that availability of this metabolite increase with 
increase of FR, as described in Figure 3.10. This carbon, nitrogen and energy source 
clearly complements glucose catabolism in HEK293-EBNA1. If in 50% FR glutamine 
reached near zero values at day 9 (the same day when occurred glucose starvation), in 
25% FR glutamine depletion happens at day 5, four days before glucose depletion. This 
additional information shows the importance of glutamine as carbon and energy source, 
simultaneously with glucose. This metabolite is also used as aminoacid or in alanine 
and proline synthesis, being efficiently recruited for cell growth. 
Considering ammonia, for all FR, levels never gone significantly above 4 mM, 
what might have as consequence futile cycles of NH4+ transport, in different extensions 
upon concentration (that would interfere with electric charges balance) 126. 
 
25 % FR 50 % FR 75 % FR 
 
Figure 3.10 – Glutamine and Ammonia production profiles in suspension stirred culture of 
HEK293-EBNA1 cell aggregates in spinner flask. The initial cell density was 2×105 cells.mL-1. The 
blue line corresponds to the growth phase in media supplemented with FBS and the red line corresponds 
to the production phase under serum-free conditions. 
Figure 3.10 also shows an accumulation of ammonia, being the maximum values 
reached in the growth phase, 4.29 mM and 3.94 mM for FR of 25% and 50%, 
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respectively, and in the production phase at 75% FR, with a maximum value of  
6.75 mM. For the small difference between ammonia accumulation in 25% and 50% 
FR, the inhibitory effect on cell growth is not evident and further analysis on this 
subject would be needed for this confirmation. Furthermore, ammonia tolerance is cell 
specific and dependent of culture conditions. Hassel et al. 49, reported HEK293 as being 
a resistant cell line to this metabolic stress, at least for 2 mM of external ammonia 
addition to medium, in comparison to other cell lines. NH3 easy diffuses across 
membrane, what favour the accumulation of NH4+, competing with potassium for 
inward transport with the Na+/K+, what make ATPase considerably increase 
maintenance energy.  
Borys et al 128 demonstrated that ammonia concentrations on the range of  
3-9 mM inhibit the N-linked glycosylation in a pH-dependent fashion (in CHO). 
Andersen and Goochee 129 reported similar inhibitory effects were described (also in 
CHO) on the O-linked glycosylation. This occurrence influences directly the 
biosynthesis and the protein quality. In this study, functional characterization was not 
performed for produced hLIF, therefore, considerations about this subject will not be 
possible yet. 
 
3.2.4. Consumption / Production rates and metabolic yields 
 
Glucose maximum specific consumption rates were higher for the 25% and 75% 
FR corresponding to a fast request from cells for this carbon source at the beginning of 
exponential growth phase but generally lower at production phase, except for the FR of 
75% (Table 3.3). This correlates with the high lactate production rates for all FR at 
growth phase, specially for 75% FR, and lower at the phase of recombinant protein 
production. According to the high specific consumption glucose rates verified at FR of 
75%, this also exhibits the higher values for lactate production. 
With this data, a direct relation about glucose consumption or lactate production 
and cell expansion capacity across different FR could not be found. 
Although, considering also the literature relation of high glucose/ high lactate 
levels, a decrease in glucose feeding could eventually be tested in order to find a 
metabolic shift. 
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Table 3.3 – Metabolic specific consumption (glucose, glutamine) and production (lactate, ammonia) 
rates. Maximum values were obtained to characterize growth exponential phase and average values were 
obtained to characterize cell culture afterwards (after day7) including production phase (the presented 
units are in μmol.106 cells.day-1) 
FR q Glu max   !"# q Lac max   $%& q Gln max   !"' q Amm max   ()) 
25% 32.8 2.16 41.2 1.16 4.96 0.309 0.921 0.342 
50% 9.83 3.31 16.1 3.69 1.84 0.494 1.64 0.359 
75% 32.1 10.0 54.4 17.9 7.66 1.52 7.31 1.85 
 
The 25% and 75% FR displayed the higher glucose and glutamine specific 
maximum consumption rates (Table 3.3), revealing high needs in this nutrients at 
exponential growth. These rates significantly decrease after growth phase in all FR, 
being the 75% FR who kept the higher consumptions along the further time of culture.  
Ammonia production rates were generally higher for exponential growth than 
later, on all FR. Particularly; in the 75% FR, a relatively high maximum at growth phase 
was found, corresponding also to a high value of glutamine consumption at exponential 
growth. This can be an immediate consequence of glutamine double deamidation 
(second ammonia molecule removal), mechanism not so evident for 25% FR witch 
glutamine consumption did not had such a significant impact in ammonia production. In 
this case, a redirection of glutamine into the aminoacid metabolism could occurred, 
once in 25% FR high culture expansion might had request this glutamine for 
biosynthesis. 
 
Maximum lactate from glucose yield (Y’lac/glu max) was obtained from 
exponential growth phase (until day 7 of culture) and average lactate from glucose yield 
(*′, -.//0-1) was calculated from daily values average (since day 7) for further culture 
time, respectively for each FR (Table 3.4). 
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Table 3.4 – Apparent yields of suspension stirred culture of HEK293-EBNA1 cell aggregates in 
spinner flask. Apparent yield of lactate from glucose as a function of culture time is represented. 
 25 % FR 50 % FR 75 % FR 
2′ 345
637
  (849)
 :. ;< =. <> =. ?@ 
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Maximum Y’lac/glu were relatively high in all FR, showing an intense request of 
carbon and energy directly from glycolysis, through fermentation, with consequent 
lactate formation. This yield increases upon FR volume increase what might reveal a 
lower metabolic efficiency in higher FR. 
Average Y’lac/glu values are generally lower than maximum Y’lac/glu as a 
consequence of a lower energetic request for cellular proliferation mechanisms after 
exponential growth. This yield also has a direct increase with FR, suggesting that in 
25% FR cells could have a more successful management of metabolic resources since it 
resulted in higher cell expansion with best use of carbon, and lower by-products (like 
lactate) biosynthesis. 
Average values above 2, that is the theoretical limit since one mole of glucose 
yields 2 moles of lactate, generally reveal that glycolysis is used as a fast pathway for 
energetic metabolism. However, no information about oxygen uptake could support 
further discussion about the extension of anaerobic or aerobic respiration along culture 
time. 
Offline measures of metabolic yields are difficult to achieve good consistency, 
once that kinetics could be not synchronized, and therefore these ratios miss estimated.   
The effect of the feeding regime on growth and aggregate size distribution was 
also evaluated for the initial cell density of 2×106 cells.mL-1, but no metabolic analysis 
was performed. This data is presented in Appendix, 6.4. 
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3.3. Effect of the global culture strategy on cell growth 
 
In Table 3.5 the data obtained in the present work is compared to different 
animal cell culture strategies described in the literature, namely for static or dynamic 
systems. 
 
Table 3.5 – Comparison of culture strategies for growth of HEK293 cells. (The results of the present 
work were obtained in static conditions for monolayer culture, and in suspension stirred conditions at 
spinner flask to compare with fed-batch culture). 
  
monolayer batch fed-batch 
spinner 
flask 
perfusion 
  
Liu et al 
93 
present 
work 
Siegwart 
et al 
1 
Liu et al 
93 
present 
work 
Siegwart 
et al 
1 
μmax (h
-1
) 0.041±0.02 0.022 0.022 0.037±0.07 0.033 0.034 
Maximum Viable Cell 
Density (10
6
 cells.mL
-1
) 
2.41±0.37 1.45 1 5.24±0.51 6.56 1 
q glu   (μmol/10
6
 cells.h
-1
) 9.3±0.6 - 0.33 8.5±0.4 3.31 0.10 
q lac  (μmol/10
6
 cells.h
-1
) 14.7±1.6 - 0.67 14.3±1.2 3.69 0.17 
Y’ lac/glu (mol.mol
-1
) 1.58 - 2.00 1.68 1.21 1.6 
  
The comparison of data obtained can bring new insights about HEK293 growth 
and animal cell metabolism. In the monolayer culture, performed in T-flask, Liu et al 93, 
reported a higher growth rate and maximum cell density when compared to the data 
obtained in the present work, 0.041 h-1 and 2.41×106 cells.mL-1 vs 0.022 h-1 and 
1.45×106 cells.mL-1, respectively. This could be due the fact that different media were 
used in the experiments: DMEM medium was used in the present work and Ham’s  
F-12, mixed with DMEM medium, was used by Liu et al. 93, where  cells were passaged 
every 4–5 days at a seeding density of 1–2×105 cells mL–1. 
Table 3.5 also shows that in our 50% FR suspension stirred culture  
(2×106 cells.mL-1 inoculum, 80 rpm) and in Liu’s fed-batch the HEK293 cells almost 
grown with same maximum growth rate, reaching closer maximum viable cell densities. 
Slower average  glucose consumption and lactate production rates were registered in our 
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study, but in this case, our experiments verified a constant feeding regime whereas  
Liu’s et al 93 HEK293 fed-batch used an increasing feeding-regime from 30% to 90%, 
which directly affects variable medium removal of lactate and differential glucose 
availability. 
Siegwart et al 1 performed a fed-batch culture with  a perfusion system in a low 
calcium serum-free medium (LC-SFM) in a online controlled process with glucose 
concentration maintained at 1 mM. This system has the capacity of keeping a µmax of 
0.034 h-1 with very low glucose consumption rate and low lactate production rate, 
having obtained a maximum cell viability of 1×106 cells.mL-1, what would give a good 
support for protein production in relatively controlled conditions (still to confirm).  
Either Siegwart et al 1 batch or perfusion methods seem to achieve low  qglu and 
low q lac, rationalizing use of glucose and inhibition by lactose, but in terms of cell 
expansion this strategies would not represent an option. The reduced influx of 1 mM 
glucose, in perfusion, could help to maintain the HEK293 cell culture without 
significant kinetic’s change, but avoiding excess of glucose to enter in secondary 
metabolic fluxes directed to lactate production. As it was mentioned before (Results and 
Discussion, 3.2.2), this could be helpful in order to avoid inhibitory concentrations of 
lactate in the medium and thus, preventing acidification and a more rational use of the 
available glucose for primary metabolism. 
 It should be noticed that Siegwart’s experiments were performed at serum-free 
conditions 
Considering the different results obtained for different experimental conditions, 
culture parameters could still be modified to enhance cell growth. Media, culture system 
and feeding regime are the main variables to optimize in order to bring higher cell 
productivities, and turn this system robust for industrial applications. 
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3.4. Recombinant Human Leukemia Inhibitory Factor 
(hLIF) Quantification and Productivity Analysis 
 
The hLIF production phase starts after the puromycin selection in the stationary 
phase of HEK293-EBNA1 cell culture and in serum-free conditions. This strategy will 
provide supernatants enriched in hLIF and free of contaminant proteins derived from 
serum, which will also significantly facilitate the subsequent recovery and purification 
process (downstream process). In order to confirm the expression of hLIF, sodium 
dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blot 
analysis of supernatants were performed ( 
Figure 3.11). 
       Coomassie     Anti-hLIF 
 
 
Figure 3.11 – SDS-PAGE (A) and Western Blot (B) Analysis of the supernatants obtained at the 
end of the production phase of hLIF in serum-free conditions. Lane A: monolayer static culture, Lane 
B: spinner flask suspension culture with FR of 25% at 80 rpm, Lane C: spinner flask suspension culture 
with FR of 50%.at 80 rpm. Lane 1: monolayer static culture, Lane 2 and 3: spinner flask suspension 
culture with FR 50% and at 80 rpm, Lane 4: hLIF standard (Chemicon). Lane MM: molecular markers. 
 
In  
Figure 3.11A, a protein band around 70kDa was observed pointing to expression 
of recombinant hLIF. Production in spinner flasks leads to more intense protein band 
around 70kDa than monolayer cultures. This was confirmed by Western-Blot analysis 
A                                                                        B 
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where a stronger hLIF band was observed for the spinner flask cultures when compared 
to monolayer ( 
Figure 3.11B). Intensity differences from Lane 2 and 3 may due the different 
load of samples on gel. The reference of hLIF displays a band around 20 kDa in the 
Western-Blot, which corresponds to the predicted molecular weight for the non 
glycosilated form. The Western Blot also revealed a band at 70 kDa, either in static or in 
spinner flask cultures, what may suggest the presence of hLIF as a dimmer. 
Enzyme Linked Immuno-Sorbent Assay (ELISA) allowed the quantification of 
hLIF and the calculation of specific productivities for the production of recombinant 
hLIF in animal cell culture (HEK293). For spinner flask experiments, specific 
productivities were calculated with basis on average viable cell density at the production 
phase, under serum-free conditions; in static culture, final cell density was used instead. 
Table 3.6 presents an overall view of the present work with the additional information 
of hLIF concentration in the bulk and specific productivities. 
 
Table 3.6 – Production of recombinant hLIF using HEK293-EBNA1 cells in different culture 
systems. Growth parameters and productivities are presented. 
Culture 
system 
Inoculum 
(cells.mL
-1
) 
Feeding 
Regime 
(day
-1
) 
FI Max 
Agg. 
Size max 
(µm) 
µmax 
 (h-1) 
hLIF 
(ng.mL-1) 
SpecifichLIF 
Production 
(ng.106 cell-1) 
Spinner 
flask 
2×104 25 % 29 ± 19.7 233 0.0014 - - 
2×105 
25 % 50 ± 10.7 278 0.055 125 ± 2.2 19.1 
50 % 32 ± 9.2 315 0.033 90.0 ± 5.72 16.4 
75 % 37 ± 9.6 660 0.021 48.1 ± 4.21 31.4 
2×106 25 % 2.6 ± 1.66 160 0.021 93.1 ± 7.20 21.4 
Monolayer 2×105 - 7.3 - 0.022 40.0 ± 1.21 37.9 
 
Of all the tested conditions and culture systems, the spinner flask culture with an 
initial cell density of 2×105 cells.mL-1 and a feeding regimen of 25% daily medium 
change was the experiment that lead to a higher recombinant hLIF volumetric 
productivity (125±2.2 ng.mL-1). A decrease in the volumetric productivity with the 
increase of the FR volume was observed, although the specific productivity is quite 
similar for the feeding regime of 25% (both 2×105 cells.mL-1 and 2×106 cells.mL-1 
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inoculums) and 50% (at 2×105 cells.mL-1 inoculum), representative of the importance of 
high number of viable cell maintenance in culture.  
The value of 75% FR with a 2×105 cells.mL-1 inoculum for specific productivity 
is similar to the obtained for the monolayer culture, 31.4 ng.106 cell-1 and  
37.9 ng.106 cell-1, respectively. However, since ratio of available surface area in 
monolayer culture is low, the volumetric productivity decreases to 40.0±1.2 ng.mL-1. 
High specific productivity of 75% FR at 2×105 cells.mL-1 reflects not a good cell 
capacity but the low maintenance of viable cells at end of culture, considereing the 
lower volumetric productivity, 48.1 ± 4.21 ng.106 cell-1 when compared with other FR 
for same inoculum.
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4. Conclusions and Future Trends  
  
48 
 
Human Leukemia Inhibitory Factor was successfully expressed in the previously 
established HEK293-EBNA1 cells. The effects of the different initial cell densities and 
feeding regime were studied towards the maximization of the recombinant protein 
productivities. 
 
4.1. Conclusions 
 
The inoculum 2×105 cell.ml-1 at 25% of daily medium change allowed to reach a 
higher number of total viable cells, 7×106 cells.mL-1 with  a µ max of 0.055 h-1. At these 
conditions, HEK293-EBNA1 aggregates at production phase reached a maximum 
diameter of 270 µm. When comparing this feeding regime with 50% and 75% a gradual 
decrease on maximum cell number and maximum growth rate was observed. 
Metabolite analysis was performed for 25%, 50% and 75% of daily medium 
change experiments with an initial cell density of 2×105 cell.ml-1. Glucose and 
glutamine were found to be complementary carbon and energy sources for cell 
metabolism. Lactate was produced as a consequence of the high glycolysis rate but not 
in severe inhibitory concentrations. Although the ammonia levels were relatively high, 
it did not seem to have an evident inhibitory role for HEK293-EBNA1 culture due to its 
relative tolerance to this metabolite (further tests would be recommended). 
All the dynamic culture systems demonstrated to be able to produce higher 
volumetric productivities of hLIF rather than in monolayer culture, being the 25% 
feeding regime at an initial cell density of 2×105 cell.ml-1 the experiment with the higher 
value, 125 ± 2.20 ng.mL-1. For this inoculum both 25 and 50% feeding regime showed 
similar specific hLIF productivities, 19.1 and 16.4 ng hLIF.106 cell-1. 
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4.2. Future trends 
 
Spinner flask experiments are useful to study parameters such as inoculum 
densities, feeding regime strategies, agitation rate, by-products inhibition and others. 
However, small scale, fully controlled bioreactors (1 L) are still needed for 
comprehension of complex biological systems for large scale expression systems. In 
these, the respiration rate (qO2), mass and heat transfer, shear stress and foam formation 
are other variables to undergo other level of biopharmaceutical engineering. 
 
Nevertheless, more studies could help to validate the proficiency of the 
parameters established for spinner flask culture and the quality of recombinant hLIF 
produced: 
 
- Test the autocrine factors involved in cell proliferation. ELISA or Western 
Blot procedures could be tried for factors like VEGF, HGF or FGF2 as 
suggested by Weil 130. 
- Quality control of produced hLIF: (1) by addressing his capacity on 46C 
mouse embryonic stem cell pluripotency maintenance; (2) through biological 
quantification of specific activity in  M1 cell line (standard test). 
- Scale-up: start a bioreactor with the previous knowledge obtained with 
the spinner flask experiments (seeding inoculum of 2×105 cell.ml-1; feeding 
regime of 25% daily medium change) 
- New Feeding Regime strategies: (1) use medium change every 12h with 
half of volumes tested before to avoid large variations on nutrient 
availability, as well as autocrine factors; (2) establish a culture feeding 
system by perfusion; and (3) test new reactor designs (ex: Wave 
Bioreactor) . 
- Downstream Process: test protocols for purification and clarification of the 
target product that is hLIF, being ion exchange chromatography one of the 
preferably strategies for this issue. 
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6.1. Carbon sources metabolism 
 
Glucose preferred catabolism in mammalian cells is summarized in Figure 6.1, 
glycolysis. Pentose cycle can be an alternative from this route, starting from  
glucose-6-P to origin ribose-6-p and NADPH. In glycolysis, the six-carbon sugar 
glucose is oxidized and split in two halves, to create two molecules of pyruvate  
(3 carbons each) from each molecule of glucose. Along the way, the cell extracts a 
relatively small amount of energy from glucose in the form of ATP, 2 ATP molecules 
collected for each glucose molecule that starts down the glycolytic path. The pyruvate 
produced has one of three metabolic fates, to either become acetyl-CoA, ethanol, or 
lactate. When oxygen is available, the pyruvate can be converted to acetyl-CoA and 
enter the Krebs Cycle, where the acetyl-CoA will be completely oxidized and generate 
ATP through oxidative phosphorylation. Fermentation is much less efficient than 
oxidative phosphorylation in making ATP, creating only 2 ATP per glucose while 
oxidative phosphorylation creates 36 ATP per glucose in mammalian cells. Oxidative 
phosphorylation does not work in the absence of oxygen, however, and in the absence 
of oxygen glycolysis is forced to a halt due to a lack of NAD+, unless NAD+ is 
regenerated through fermentation.  
 
Glutamine acts complementary as carbon source; the catabolism of glutamine is 
schematically represented in Figure 6.2. Glutamine is converted to glutamate by 
glutaminase or several other enzymes by the removal of the amide nitrogen. 
Transamination or deamination of glutamate produces a-ketoglutarate which feeds into 
the citric acid cycle. 
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Figure 6.1 - Glycolysis Pathway in Homo sapien. Adapted from Biocarta 131 
 
 
 Figure 6.2 - Catabolic Pathways Glutamine, and Proline. Adapted from Biocarta 
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6.2. Cell viability 
 
Cell viability was controlled daily manually trough trypan blue exclusion 
method. Cell viability results are presented in Table 6.1. As observed in this data, 
HEK293-EBNA1 preserve high viability across all culture conditions, sustaining to be a 
preferred cell line for animal cell technology. In most of experiments cell viability was 
above 97%, except for the initial cell density of 2×106 cells.mL-1 and FR of 75% where, 
as discussed before, some operational error could have occurred. Negative values were 
not considered for average cell viability calculation. 
 
Table 6.1 – Cell viability for each day of HEK293 culture (trypan blue exclusion method) 
Initial 
cell 
density 
2×104 
cells.mL-1 2×10
5
 cells.mL-1 2×106 cells.mL-1 
FR 
Day 
25% 25% 50% 75% 25% 50% 75% 
0 100% 100% 100% 94% 100% 100% 100% 
1 93% 98% 96% 98% 100% 100% 100% 
2 92% 99% 98% 96% 98% 100% 99% 
3 98% 100% 100% 100% 100% 99% 98% 
4 96% 100% 100% 98% 99% 98% 96% 
5 100% 99% 100% 98% 99% 100% 91% 
6 100% 100% 99% 100% 100% 98% 88% 
7 100% 100% 100% 99% 100% 99% 83% 
8 98% - - 98% 100% 98% 85% 
9 95% 91% 97% 99% 100% 99% 79% 
10 100% 100% 100% 94% 100% 99% 69% 
11 94% 100% 99% 96% 100% 98% 72% 
12 92% 100% 99% 99% 100% 99% -178% 
13 99% 99% 99% 100%   -76% 
14 100% 100% 100% 99%    
15 98% 100% 100% 99%    
16 98% 100% 99% 99%    
17 90% 100% 100% 100%    
18 98%   99%    
19    -5%    
20        
Average 
Cell 
Viability 
97% 99% 99% 98% 100% 99% 88% 
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Cell viability was tested also with LDH kit CytoTox96 (Promega) and compared 
with the previous data for the initial cell density of 2×106 cells.mL-1 and FR of 25%, 
obtained by trypan blue exclusion method. In Figure 6.3, the trypan blue methodology 
proves to be more accurate than spectrophotometric CytoTox96. CytoTox96 presents 
negative values for total cell number revealing that for lower rates of cell death the 
results are under the limit of detection of the method. 
 
 
Figure 6.3 – Assessment of dead cell number by trypan blue exclusion method ( ) and LDH kit 
CytoTox96 ( ) (Promega). HEK293-EBNA1 cells at an initial cell density of 2×106 cells.mL-1 and 
FR of 25%, 
 
Although the variability and accuracy of each method, when compared to the 
total cell number of viable cells, both methods support a low number of dead cells 
observed during culture time (lines are overhead), as is described in Figure 6.4. 
 
 
Figure 6.4 – Total cell number of HEK293 viable cells ( ) compared to dead cells number by 
trypan blue exclusion method ( ) and LDH kit CytoTox96 ( ) (Promega). Initial cell density of 
2×106 cells.mL-1 and FR of 25%. 
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6.3. Fitting curves to growth experimental data 
 
Due to the great variability of experimental data it is difficult to establish an 
accurate exponential phase, being representative of overall culture growth. To help with 
this issue, a non-linear fitting was performed to all growth experiments using Origin 
software using the Non Linear Curve Fit routine according to Equation 6.3: 
* =
CDECDFG
H(/I)
J + KLH  (6.3) 
 
where Ai and Ai+1 represent the viable cell number at day i and at day i+1, at 
corresponding times x0 and x, respectively. 
The software fits to experimental data (outlier points were previously excluded) 
and returns 100 points, statistical validated by ANOVA test. These output points were 
ploted in Microsoft Excel and a linear regression was established for exponential phase 
data, as can be seen in the model presented in Figure 6.5. From the linear regression 
equation  = .  +  can be obtained the  (m value). 
 
 
 
Figure 6.5 – Example of Non Linear Curve Fit to experimental data. The data reports the effect of 
feeding regime on growth of HEK293-EBNA1 in spinner flask and at 80 rpm Here is presented the 
initial cell density of 2×105 cells.mL-1 and a feeding regimen of 25% daily medium change. In red are 
presented the 100 points output Logistic regression for the experiment. In blue are presented the selected 
experimental data in the input of this function. The black line represents the linear regression to the points 
in the exponential part of growth, R2 validates the accuracy of the linear regression. 
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within the spinner flask volume. This strategy made possible to shorten the 
growth/production cycle in about 5 days when compared to the previous experiments, 
what could stand as an advantage. One of the major negative points in this high initial 
cell density (2×106 cells.ml-1) strategy is related with the time and material consumption 
in inoculum production, the added value to culture maintenance and development of a 
large storage bank at low temperatures. Such disadvantage would be minimized if 
recycle of the cells after the fed-batch cycle could be successfully established. No 
analysis about the carbon source consumption (glucose and glutamine) and secondary 
metabolites production (lactate and ammonia) were performed for these experiments. 
In Table 6.2, the specific growth rate was found to be quite similar both in 25% 
and 50% FR and therefore similar time of duplication. Higher cell expansion could be 
reached in 25% FR, apparently not significant in terms of the final cell density, similar 
with 50% FR. 
 
Table 6.2 – Maximal growth rates, duplication time and maximal fold increase in total cell number 
for a inoculum of 2×105 cells.mL-1 at different feeding regimen in a spinner flask at 80 rpm. 
Feeding Regime µ max (h-1) td (h) 
Fold 
Increase 
X max 
(106 cells.mL-1) 
X prod 
(106 cells.mL-1)
 
25 % 0.021 33.0 2.66 7.73 4.35 
50 % 0.022 31.5 2.63 6.13 4.59 
75 % - - - 4.00 0.178 
 
The higher medium renewal (75%) affected negatively the cell growth, 
corresponding to larger exponential phases and, consequently, lower µ max values. Both 
25% and 50% FR led to similar maximum fold increase, and also maximum growth 
rates were quite similar, 0.021 and 0.022, respectively. At these high initial cell 
densities, the growth phase is shorter being the steady phase plateau reached faster, 
achieving shorter culture times by production cycle – culture ends at day 12. 
Nevertheless, the 25% daily medium change confirmed to be the most useful and the 
most economic feeding regime strategy found to obtain the highest cell density. The 
75% feeding regime registered negative value for µ max (not presented) due to high cell 
loss. 
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regime, within the initial cell density of 
 is represented in Figure 
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reasons: 1) the limited initial cell number did not allowed aggregate expansion; 2) the 
high volume perturbation interfered in aggregate stability. 
 
Figure 6.8 indicates clearly that at this inoculum density and for all FR it was 
observed a large number of cells in suspension at the end of the culture time. In all the 
cases, it was observed a good homogeneity in aggregate size distribution.  
Day 5 Day 12 
 
  
A 
  
B 
  
C 
Figure 6.8 – Photograph of HEK293-EBNA1 cell aggregates along the culture (Day 5 and 12). A – 
feeding regimen of 25%; B – feeding regimen of 50%; C – feeding regimen of 75%, all with a start 
inoculum of 2×106 cells.mL-1 and with daily medium change. Scale bar represents 100 µm. 
 
In Figure 6.8C is evident the incapacity of growth and aggregate expansion of 
the culture. Here, microscopy photographs support the statistical data about aggregate 
hydrodynamics. This data suggests that higher volume perturbations on the system may 
be negative to cell growth and also for hydrodynamics consistency and morphology of 
aggregates, confirming the data obtained in the cultures with the initial cell density of 
2×105 cells.mL-1. As previously discussed, the cell aggregate diameters for these 
experiments are still far from any hypothesis of nutrient diffusion limitations. 
 
 
70 
 
 
